baricitinib vs ZL-82

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK · full Atopic Dermatitis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Phase 3 in Atopic Dermatitissmall molecule
Reliable signal

NCT03334396 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.

Next expected readout: May 2030 · NCT07262983 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib) (16 Weeks): 2mg Baricitinib 10.6% | 4mg Baricitinib 13.8% vs Placebo 4.5% (met)

Result source: NCT03334422

ZL-82

Developed by Chengdu Zenitar Biomedical Technology

Phase 2 in Atopic DermatitisSmall molecule (oral JAK3 inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07193589 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibZL-82
EASI-7531.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
—Not reported
IGA 0/1 with 2-point improvement13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
—Not reported
EASI-9016% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
—Not reported
EASI, % change-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
—Not reported

EASI-75

baricitinib
31.5% vs 17.2%+14.3 vs placebo4 mg · wk 16 · n 92NCT03428100
65 other results
  • 27.6% vs 17.2% 2 mg · wk 16 · n 185 · Phase 3 · primary NCT03428100
  • 29.5% vs 8.2% 2 mg · wk 16 · n 146 · Phase 3 · primary NCT03435081
  • 39.8% vs 54.3% 4 mg · wk 104 · n 264 · Phase 3 · secondary NCT03334435
  • 73.8% vs 43.5% 4 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 37% vs 26.9% 4 mg · wk 52 · n 92 · Phase 3 · secondary NCT03428100
  • 25% vs 17.2% 4 mg · wk 24 · n 92 · Phase 3 · secondary NCT03428100
  • 47.7% vs 22.9% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 40.9% vs 54.3% 2 mg · wk 104 · n 193 · Phase 3 · secondary NCT03334435
  • 30.3% vs 26.9% 2 mg · wk 52 · n 185 · Phase 3 · secondary NCT03428100
  • 27.6% vs 17.2% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 12.9% vs 8.2% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 76.7% vs 55.1% 4 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 79.8% vs 44.6% 4 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 93% vs 63.3% 4 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 51.4% vs 38.5% 4 mg · wk 52 · n 70 · Phase 3 · secondary NCT03334435
  • 42.9% vs 38.2% 4 mg · wk 52 · n 63 · Phase 3 · secondary NCT03334435
  • 51.4% vs 44.2% 4 mg · wk 36 · n 70 · Phase 3 · secondary NCT03334435
  • 44.4% vs 47.1% 4 mg · wk 36 · n 63 · Phase 3 · secondary NCT03334435
  • 24.8% vs 8.8% 4 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334396
  • 21.1% vs 6.1% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 61.5% vs 71.4% 4 mg · wk 68 · n 39 · Phase 3 · secondary NCT03334435
  • 64.3% vs 42.3% 4 mg · wk 16 · n 70 · Phase 3 · secondary NCT03334435
  • 55.6% vs 55.9% 4 mg · wk 16 · n 63 · Phase 3 · secondary NCT03334435
  • 58.3% vs 43.5% 2 mg · wk 104 · n 84 · Phase 3 · secondary NCT03334435
  • 72.8% vs 43.5% 2 mg · wk 104 · n 92 · Phase 3 · secondary NCT03334435
  • 74.4% vs 55.1% 2 mg · wk 104 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 55.1% 2 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 58.3% vs 44.6% 2 mg · wk 68 · n 84 · Phase 3 · secondary NCT03334435
  • 73.9% vs 44.6% 2 mg · wk 68 · n 92 · Phase 3 · secondary NCT03334435
  • 68.2% vs 72.4% 2 mg · wk 104 · n 22 · Phase 3 · secondary NCT03428100
  • 76.7% vs 63.3% 2 mg · wk 68 · n 43 · Phase 3 · secondary NCT03334435
  • 83.3% vs 63.3% 2 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 53.2% vs 71.4% 2 mg · wk 68 · n 47 · Phase 3 · secondary NCT03334435
  • 55.1% vs 71.4% 2 mg · wk 68 · n 49 · Phase 3 · secondary NCT03334435
  • 64.8% vs 38.5% 2 mg · wk 52 · n 54 · Phase 3 · secondary NCT03334435
  • 52.8% vs 38.2% 2 mg · wk 52 · n 53 · Phase 3 · secondary NCT03334435
  • 74.1% vs 44.2% 2 mg · wk 36 · n 54 · Phase 3 · secondary NCT03334435
  • 47.2% vs 47.1% 2 mg · wk 36 · n 53 · Phase 3 · secondary NCT03334435
  • 18.7% vs 8.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 17.9% vs 6.1% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 70.4% vs 42.3% 2 mg · wk 16 · n 54 · Phase 3 · secondary NCT03334435
  • 67.9% vs 55.9% 2 mg · wk 16 · n 53 · Phase 3 · secondary NCT03334435
  • 43.1% vs 22.9% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 58.2% vs 43.5% 1 mg · wk 104 · n 91 · Phase 3 · secondary NCT03334435
  • 63.6% vs 62.1% 2 mg · wk 68 · n 22 · Phase 3 · secondary NCT03428100
  • 79.2% vs 55.1% 1 mg · wk 104 · n 48 · Phase 3 · secondary NCT03334435
  • 65.6% vs 54.3% 1 mg · wk 104 · n 32 · Phase 3 · secondary NCT03334435
  • 70.6% vs 72.4% 1 mg · wk 104 · n 34 · Phase 3 · secondary NCT03428100
  • 69.2% vs 44.6% 1 mg · wk 68 · n 91 · Phase 3 · secondary NCT03334435
  • 89.6% vs 63.3% 1 mg · wk 68 · n 48 · Phase 3 · secondary NCT03334435
  • 44.4% vs 71.4% 1 mg · wk 68 · n 45 · Phase 3 · secondary NCT03334435
  • 76.5% vs 62.1% 1 mg · wk 68 · n 34 · Phase 3 · secondary NCT03428100
  • 51.1% vs 38.5% 1 mg · wk 52 · n 45 · Phase 3 · secondary NCT03334435
  • 33.3% vs 26.9% 1 mg · wk 52 · n 93 · Phase 3 · secondary NCT03428100
  • 46.7% vs 44.2% 1 mg · wk 36 · n 45 · Phase 3 · secondary NCT03334435
  • 30.1% vs 17.2% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 17.3% vs 8.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 12.8% vs 6.1% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 62.2% vs 42.3% 1 mg · wk 16 · n 45 · Phase 3 · secondary NCT03334435
  • 22.6% vs 17.2% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 32.2% vs 32% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 40% vs 32% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 52.5% vs 32% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 85.7% vs 72.4% 4 mg · wk 104 · n 7 · Phase 3 · secondary NCT03428100
  • 57.1% vs 62.1% 4 mg · wk 68 · n 7 · Phase 3 · secondary NCT03428100
ZL-82
—Not reported

IGA 0/1 with 2-point improvement

baricitinib
13% vs 12.9%+0.1 vs placebo4 mg · wk 24 · n 92NCT03428100
5 other results
  • 21.7% vs 9.7% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 18.9% vs 12.9% 2 mg · wk 24 · n 185 · Phase 3 · secondary NCT03428100
  • 15.1% vs 9.7% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.4% vs 12.9% 1 mg · wk 24 · n 93 · Phase 3 · secondary NCT03428100
  • 12.9% vs 9.7% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
ZL-82
—Not reported

EASI-90

baricitinib
16% vs 4.8%+11.2 vs placebo4 mg · wk 16 · n 125NCT03334396
15 other results
  • 13% vs 2.5% 4 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 14.1% vs 6.5% 4 mg · wk 16 · n 92 · Phase 3 · secondary NCT03428100
  • 24.3% vs 13.8% 4 mg · wk 16 · n 111 · Phase 3 · secondary NCT03733301
  • 10.6% vs 4.8% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334396
  • 8.9% vs 2.5% 2 mg · wk 16 · n 123 · Phase 3 · secondary NCT03334422
  • 10.3% vs 6.5% 2 mg · wk 16 · n 185 · Phase 3 · secondary NCT03428100
  • 20.5% vs 3.4% 2 mg · wk 16 · n 146 · Phase 3 · secondary NCT03435081
  • 16.5% vs 13.8% 2 mg · wk 16 · n 109 · Phase 3 · secondary NCT03733301
  • 8.7% vs 4.8% 1 mg · wk 16 · n 127 · Phase 3 · secondary NCT03334396
  • 6.4% vs 2.5% 1 mg · wk 16 · n 125 · Phase 3 · secondary NCT03334422
  • 8.6% vs 6.5% 1 mg · wk 16 · n 93 · Phase 3 · secondary NCT03428100
  • 7.5% vs 3.4% 1 mg · wk 16 · n 147 · Phase 3 · secondary NCT03435081
  • 11.6% vs 12.3% Low Dose · wk 16 · n 121 · Phase 3 · secondary NCT03952559
  • 21.7% vs 12.3% Medium Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
  • 30% vs 12.3% High Dose · wk 16 · n 120 · Phase 3 · secondary NCT03952559
ZL-82
—Not reported

EASI, % change

baricitinib
-59.4% vs -34.8%−24.5 vs placebo4 mg · wk 16 · n 70NCT03334396
12 other results
  • -54.9% vs -28.9% 4 mg · wk 16 · n 49 · Phase 3 · secondary NCT03334422
  • -63.3% vs -42.7% 4 mg · wk 16 · n 65 · Phase 3 · secondary NCT03428100
  • -67.2% vs -45.1% 4 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -51.9% vs -34.8% 2 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -56.0% vs -42.7% 2 mg · wk 16 · n 144 · Phase 3 · secondary NCT03428100
  • -54.8% vs -28.9% 2 mg · wk 16 · n 40 · Phase 3 · secondary NCT03334422
  • -54.4% vs -34.1% 2 mg · wk 16 · n 62 · Phase 3 · secondary NCT03435081
  • -58.2% vs -45.1% 2 mg · wk 16 · n 100 · Phase 3 · secondary NCT03733301
  • -48.2% vs -34.8% 1 mg · wk 16 · n 52 · Phase 3 · secondary NCT03334396
  • -41.7% vs -28.9% 1 mg · wk 16 · n 34 · Phase 3 · secondary NCT03334422
  • -60.3% vs -42.7% 1 mg · wk 16 · n 61 · Phase 3 · secondary NCT03428100
  • -46.7% vs -34.1% 1 mg · wk 16 · n 47 · Phase 3 · secondary NCT03435081
ZL-82
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ZL-82: no structured comparison results are available for Atopic Dermatitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. baricitinib: 4 of 4 rows · ZL-82: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Dropout rate
4%4 mga
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.7%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.9%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
98%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
97.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
7.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
6.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
14%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
13%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
8.3%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
32.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%4 mga
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
—4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.6%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.7%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.6%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
—1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
2.7%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
0.9%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
—4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
8.1%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
Serious AEs
1.6%4 mga
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 50 more results
0%4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0%1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4%2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.3%1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0.8%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
1.7%Low Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
—Medium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0.8%Mid Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
0%High Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
9.5%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
13.1%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
5.4%4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
6.4%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
3.3%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
4.2%2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
9.4%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
1.1%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
2.2%1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
28.6%4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16.7%Placebo to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18.8%4 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.9%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
4.5%2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
11.1%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
19.2%2 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
9.1%Placebo to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
16%2 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
12.5%2 mg to 1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.5%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.9%1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
15.4%1 mg to 2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
21.4%1 mg to 4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
—2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
1.4%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0.7%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
0%1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.6%4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.8%2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.6%4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
5.4%2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
4 mga
nasopharyngitis 9.6% (placebo 10.4%)
headache 8% (placebo 6.4%)
cough 3.2% (placebo 0.8%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 47 more results
4 mg
abdominal pain 12.5% (placebo 0.4%)
nausea 12.5% (placebo 0.8%)
oedema peripheral 12.5% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
headache 11.4% (placebo 6.4%)
nasopharyngitis 9.8% (placebo 10.4%)
abdominal pain 2.4% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
pyrexia 12.5% (placebo 0%)
urinary tract infection 12.5% (placebo 1.6%)
abdominal pain 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 17.3% (placebo 10.4%)
diarrhoea 7.1% (placebo 2.8%)
headache 5.5% (placebo 6.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
pyrexia 20% (placebo 0%)
abdominal pain 0% (placebo 0.4%)
anaemia 0% (placebo 0.4%)
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4 mg
headache 8.9% (placebo 2%)
nasopharyngitis 8.1% (placebo 12.3%)
blood creatine phosphokinase increased 5.7% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 mg
nasopharyngitis 13% (placebo 12.3%)
headache 7.3% (placebo 2%)
herpes simplex 5.7% (placebo 0.8%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1 mg
nasopharyngitis 10.5% (placebo 12.3%)
headache 4.8% (placebo 2%)
blood creatine phosphokinase increased 3.2% (placebo 0.4%)
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
High Dose
abdominal pain 5% (placebo 2.5%)
acne 5% (placebo 4.1%)
headache 5% (placebo 8.2%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Low Dose
headache 5.8% (placebo 8.2%)
bronchitis 5% (placebo 0.8%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
Mid Dose
headache 9.2% (placebo 8.2%)
abdominal pain 4.2% (placebo 2.5%)
covid-19 4.2% (placebo 2.5%)
NCT03952559 · Phase 3 · registry result, not featured evidence
High Dose
nasopharyngitis 6.1% (placebo 4.9%)
abdominal pain upper 3% (placebo 0.8%)
chapped lips 3% (placebo 0%)
NCT03952559 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 11% (placebo 2.2%)
herpes zoster 9.8% (placebo 0%)
nasopharyngitis 9.8% (placebo 5.4%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 2.2%)
nasopharyngitis 13.1% (placebo 5.4%)
blood creatine phosphokinase increased 6% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 16.4% (placebo 5.4%)
upper respiratory tract infection 5.9% (placebo 4.3%)
oral herpes 5.4% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 13.3% (placebo 2.2%)
nasopharyngitis 10.8% (placebo 5.4%)
headache 5.6% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
covid-19 15.2% (placebo 2.2%)
nasopharyngitis 10.9% (placebo 5.4%)
headache 5.4% (placebo 3.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.5% (placebo 5.4%)
urinary tract infection 7.1% (placebo 1.1%)
covid-19 4.8% (placebo 2.2%)
NCT03334435 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 13.8% (placebo 5.4%)
headache 6% (placebo 3.3%)
upper respiratory tract infection 5.6% (placebo 4.3%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 21.9% (placebo 2.2%)
alanine aminotransferase increased 9.4% (placebo 0%)
dermal cyst 6.3% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
covid-19 9.9% (placebo 2.2%)
vulvovaginal candidiasis 6.7% (placebo 0%)
folliculitis 5.5% (placebo 0%)
NCT03334435 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 20% (placebo 5.4%)
pyrexia 4.4% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 1.1%)
NCT03334435 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 37% (placebo 10.3%)
influenza 15.2% (placebo 3.4%)
headache 10.9% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
covid-19 16.7% (placebo 13.8%)
dysmenorrhoea 14.3% (placebo 0%)
upper respiratory tract infection 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 57.1% (placebo 10.3%)
covid-19 28.6% (placebo 13.8%)
gastroenteritis 28.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 4 mg
nasopharyngitis 50% (placebo 10.3%)
abdominal pain upper 16.7% (placebo 0%)
migraine 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 2 mg
nasopharyngitis 18.8% (placebo 10.3%)
upper respiratory tract infection 18.8% (placebo 3.4%)
arthralgia 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
4 mg to 4 mg
covid-19 25% (placebo 13.8%)
bronchitis 18.8% (placebo 0%)
herpes simplex 18.8% (placebo 6.9%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 19.6% (placebo 10.3%)
influenza 8.2% (placebo 3.4%)
headache 7.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 22.7% (placebo 10.3%)
covid-19 18.2% (placebo 13.8%)
herpes zoster 13.6% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
covid-19 14.8% (placebo 13.8%)
vulvovaginal candidiasis 14.3% (placebo 0%)
nasopharyngitis 11.1% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 4 mg
covid-19 19.2% (placebo 13.8%)
herpes zoster 15.4% (placebo 0%)
skin infection 15.4% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
Placebo to 2 mg
acne 9.1% (placebo 0%)
anaemia 9.1% (placebo 0%)
covid-19 9.1% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 2 mg
headache 20% (placebo 3.4%)
vulvovaginal candidiasis 20% (placebo 0%)
covid-19 16% (placebo 13.8%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg to 1 mg
nasopharyngitis 33.3% (placebo 10.3%)
covid-19 12.5% (placebo 13.8%)
pain in extremity 12.5% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
nasopharyngitis 17.2% (placebo 10.3%)
folliculitis 9.7% (placebo 0%)
headache 8.6% (placebo 3.4%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg
dysmenorrhoea 23.1% (placebo 0%)
covid-19 17.6% (placebo 13.8%)
nasopharyngitis 11.8% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 2 mg
herpes simplex 15.4% (placebo 6.9%)
herpes zoster 15.4% (placebo 0%)
nasopharyngitis 15.4% (placebo 10.3%)
NCT03428100 · Phase 3 · registry result, not featured evidence
1 mg to 4 mg
conjunctivitis 21.4% (placebo 0%)
covid-19 21.4% (placebo 13.8%)
uterine polypectomy 16.7% (placebo 0%)
NCT03428100 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 6.9% (placebo 6.2%)
nasopharyngitis 6.2% (placebo 7.5%)
diarrhoea 4.1% (placebo 1.4%)
NCT03435081 · Phase 3 · registry result, not featured evidence
2 mg
prostate cancer 9.1% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 6.2%)
urinary tract infection 8.6% (placebo 2.1%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 6.1% (placebo 6.2%)
back pain 2% (placebo 0.7%)
blood creatine phosphokinase increased 2% (placebo 0.7%)
NCT03435081 · Phase 3 · registry result, not featured evidence
1 mg
upper respiratory tract infection 10.5% (placebo 6.2%)
ovarian cyst ruptured 6.7% (placebo 0%)
actinic keratosis 5.3% (placebo 0%)
NCT03435081 · Phase 3 · registry result, not featured evidence
4 mg
nasopharyngitis 15.3% (placebo 12%)
folliculitis 5.4% (placebo 0%)
upper respiratory tract infection 2.7% (placebo 1.9%)
NCT03733301 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 11% (placebo 12%)
upper respiratory tract infection 7.3% (placebo 1.9%)
folliculitis 3.7% (placebo 0%)
NCT03733301 · Phase 3 · registry result, not featured evidence
4 mg
blood creatine phosphokinase increased 13.2% (placebo 2%)
headache 13.2% (placebo 0%)
nasopharyngitis 10.5% (placebo 4.1%)
NCT02576938 · Phase 2 · registry result, not featured evidence
2 mg
dermatitis atopic 8.1% (placebo 10.2%)
gastrooesophageal reflux disease 5.4% (placebo 0%)
headache 5.4% (placebo 0%)
NCT02576938 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 42 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

IGA 0 1 Improvement 16.8% (n=125) vs 4.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 5 more results
10.4% (n=125) vs 2.4% (n=249) placebo @ 4wk4 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.4% (n=123) vs 4.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9% (n=123) vs 2.4% (n=249) placebo @ 4wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.8% (n=127) vs 4.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.1% (n=127) vs 2.4% (n=249) placebo @ 4wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
EASI-75 24.8% (n=125) vs 8.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 65 more results
21.1% (n=123) vs 6.1% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
64.3% (n=70) vs 42.3% (n=52) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
51.4% (n=70) vs 44.2% (n=52) placebo @ 36wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
51.4% (n=70) vs 38.5% (n=52) placebo @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
55.6% (n=63) vs 55.9% (n=34) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
44.4% (n=63) vs 47.1% (n=34) placebo @ 36wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
42.9% (n=63) vs 38.2% (n=34) placebo @ 52wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
79.8% (n=84) vs 45.2% (n=84) placebo @ 68wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
73.8% (n=84) vs 41.7% (n=84) placebo @ 104wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
93% (n=43) vs 72.1% (n=43) placebo @ 68wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
76.7% (n=43) vs 67.4% (n=43) placebo @ 104wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
61.5% (n=39) vs 70% (n=50) placebo @ 68wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
39.8% (n=264) vs 54.3% (n=70) placebo @ 104wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
31.5% (n=92) vs 17.2% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
25% (n=92) vs 17.2% (n=93) placebo @ 24wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
37% (n=92) vs 26.9% (n=93) placebo @ 52wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
57.1% (n=7) vs 62.1% (n=29) placebo @ 68wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
85.7% (n=7) vs 72.4% (n=29) placebo @ 104wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
47.7% (n=111) vs 22.9% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
18.7% (n=123) vs 8.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
17.9% (n=123) vs 6.1% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
70.4% (n=54) vs 42.3% (n=52) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
74.1% (n=54) vs 44.2% (n=52) placebo @ 36wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
64.8% (n=54) vs 38.5% (n=52) placebo @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
67.9% (n=53) vs 55.9% (n=34) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
47.2% (n=53) vs 47.1% (n=34) placebo @ 36wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
52.8% (n=53) vs 38.2% (n=34) placebo @ 52wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
58.3% (n=84) vs 45.2% (n=84) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
73.9% (n=92) vs 45.2% (n=84) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
58.3% (n=84) vs 41.7% (n=84) placebo @ 104wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
72.8% (n=92) vs 41.7% (n=84) placebo @ 104wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
76.7% (n=43) vs 72.1% (n=43) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
83.3% (n=48) vs 72.1% (n=43) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
74.4% (n=43) vs 67.4% (n=43) placebo @ 104wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
83.3% (n=48) vs 67.4% (n=43) placebo @ 104wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
53.2% (n=47) vs 70% (n=50) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
55.1% (n=49) vs 70% (n=50) placebo @ 68wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
40.9% (n=193) vs 54.3% (n=70) placebo @ 104wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
27.6% (n=185) vs 17.2% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
27.6% (n=185) vs 17.2% (n=93) placebo @ 24wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
30.3% (n=185) vs 26.9% (n=93) placebo @ 52wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
63.6% (n=22) vs 62.1% (n=29) placebo @ 68wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
68.2% (n=22) vs 72.4% (n=29) placebo @ 104wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
29.5% (n=146) vs 8.2% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
43.1% (n=109) vs 22.9% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
17.3% (n=127) vs 8.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
12.8% (n=125) vs 6.1% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
62.2% (n=45) vs 42.3% (n=52) placebo @ 16wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
46.7% (n=45) vs 44.2% (n=52) placebo @ 36wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
51.1% (n=45) vs 38.5% (n=52) placebo @ 52wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
69.2% (n=91) vs 45.2% (n=84) placebo @ 68wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
58.2% (n=91) vs 41.7% (n=84) placebo @ 104wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
89.6% (n=48) vs 72.1% (n=43) placebo @ 68wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
79.2% (n=48) vs 67.4% (n=43) placebo @ 104wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
44.4% (n=45) vs 70% (n=50) placebo @ 68wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
65.6% (n=32) vs 54.3% (n=70) placebo @ 104wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
22.6% (n=93) vs 17.2% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
30.1% (n=93) vs 17.2% (n=93) placebo @ 24wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
33.3% (n=93) vs 26.9% (n=93) placebo @ 52wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
76.5% (n=34) vs 62.1% (n=29) placebo @ 68wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
70.6% (n=34) vs 72.4% (n=29) placebo @ 104wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
12.9% (n=147) vs 8.2% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
32.2% (n=121) vs 32% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
40% (n=120) vs 32% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
52.5% (n=120) vs 32% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
EASI-90 16% (n=125) vs 4.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
13% (n=123) vs 2.5% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
14.1% (n=92) vs 6.5% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
24.3% (n=111) vs 13.8% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
10.6% (n=123) vs 4.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.9% (n=123) vs 2.5% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
10.3% (n=185) vs 6.5% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
20.5% (n=146) vs 3.4% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
16.5% (n=109) vs 13.8% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
8.7% (n=127) vs 4.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.4% (n=125) vs 2.5% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.6% (n=93) vs 6.5% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.5% (n=147) vs 3.4% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
11.6% (n=121) vs 12.3% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
21.7% (n=120) vs 12.3% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
30% (n=120) vs 12.3% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
EASI -59.36% (n=70) vs -34.82% (n=71) placebo @ 16wk4 mg
percent change · % of baseline
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 12 more results
-54.88% (n=49) vs -28.91% (n=52) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-63.31% (n=65) vs -42.69% (n=54) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-67.21% (n=100) vs -45.08% (n=90) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-51.89% (n=52) vs -34.82% (n=71) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-54.8% (n=40) vs -28.91% (n=52) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-56.05% (n=144) vs -42.69% (n=54) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-54.37% (n=62) vs -34.07% (n=28) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-58.16% (n=100) vs -45.08% (n=90) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-48.22% (n=52) vs -34.82% (n=71) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-41.68% (n=34) vs -28.91% (n=52) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-60.34% (n=61) vs -42.69% (n=54) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-46.66% (n=47) vs -34.07% (n=28) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
SCORAD75 10.4% (n=125) vs 1.2% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
11.4% (n=123) vs 1.6% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.5% (n=92) vs 1.1% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
18% (n=111) vs 7.3% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
7.3% (n=123) vs 1.2% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.3% (n=123) vs 1.6% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8.1% (n=185) vs 1.1% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
14.4% (n=146) vs 2.7% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
11% (n=109) vs 7.3% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
5.5% (n=127) vs 1.2% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.8% (n=125) vs 1.6% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.5% (n=93) vs 1.1% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=147) vs 2.7% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
7.4% (n=121) vs 9.8% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
15.8% (n=120) vs 9.8% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
20% (n=120) vs 9.8% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
Itch NRS 4-Point Improvement 21.5% (n=107) vs 7.2% (n=222) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
18.7% (n=107) vs 4.7% (n=213) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
41% (n=61) vs 32.6% (n=43) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
46.4% (n=56) vs 37.5% (n=32) placebo @ 16wk4 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
38.2% (n=76) vs 8.2% (n=85) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
44% (n=100) vs 20.2% (n=104) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
12% (n=100) vs 7.2% (n=222) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
15.1% (n=106) vs 4.7% (n=213) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
32.6% (n=43) vs 32.6% (n=43) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
45.8% (n=48) vs 37.5% (n=32) placebo @ 16wk2 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
22.9% (n=166) vs 8.2% (n=85) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
25.2% (n=131) vs 5.7% (n=123) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
38.1% (n=97) vs 20.2% (n=104) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
10.5% (n=105) vs 7.2% (n=222) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6% (n=100) vs 4.7% (n=213) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
25.8% (n=31) vs 32.6% (n=43) placebo @ 16wk1 mg
NCT03334435 · Phase 3 · registry result, not featured evidence
23.1% (n=78) vs 8.2% (n=85) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
15.9% (n=132) vs 5.7% (n=123) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
ADSS Item 2 -1.42 vs -0.84 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
-1.38 vs -0.8 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.42 vs -0.63 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-1.42 vs -0.51 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.04 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.21 vs -0.8 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-0.85 vs -0.63 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.99 vs -0.4 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-1.33 vs -0.51 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.21 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.1 vs -0.8 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.05 vs -0.63 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-0.62 vs -0.4 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-0.35 vs -0.42 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.43 vs -0.42 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-0.55 vs -0.42 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
Skin Pain NRS -1.93 vs -0.84 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
-2.49 vs -0.86 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.02 vs -1.56 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-3.73 vs -2.06 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.58 vs -0.84 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.61 vs -0.86 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -1.56 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.4 vs -1.03 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-3.22 vs -2.06 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-1.92 vs -0.84 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.09 vs -0.86 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.27 vs -1.56 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-2.16 vs -1.03 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-1.23 vs -1.15 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-1.56 vs -1.15 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-1.77 vs -1.15 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
EASI-50 41.6% (n=125) vs 15.3% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
29.3% (n=123) vs 12.3% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
52.2% (n=92) vs 35.5% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
70.3% (n=111) vs 41.3% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
61% (n=38) vs 37% (n=49) placebo @ 16wk4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
30.1% (n=123) vs 15.3% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.6% (n=123) vs 12.3% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
51.4% (n=185) vs 35.5% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
34.9% (n=146) vs 12.9% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
64.2% (n=109) vs 41.3% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
57% (n=37) vs 37% (n=49) placebo @ 16wk2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
26% (n=127) vs 15.3% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
18.4% (n=125) vs 12.3% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
45.2% (n=93) vs 35.5% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
19.7% (n=147) vs 12.9% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
59.5% (n=121) vs 55.7% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
60.8% (n=120) vs 55.7% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
71.7% (n=120) vs 55.7% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
IGA 0 1.6% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.3% (n=92) vs 0% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
8.1% (n=111) vs 2.8% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.1% (n=123) vs 1.6% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.1% (n=185) vs 0% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2.7% (n=146) vs 0.7% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.7% (n=109) vs 2.8% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
1.6% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.4% (n=125) vs 1.6% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=93) vs 0% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=147) vs 0.7% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
5% (n=121) vs 4.1% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
5% (n=120) vs 4.1% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
12.5% (n=120) vs 4.1% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
SCORAD -28.3 vs -13.51 placebo score @ 16wk4 mg
absolute change · score
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
-27.5 vs -13.35 placebo score @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-31.74 vs -21.98 placebo score @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-35.78 vs -21.4 placebo score @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-26.54 vs -11.89 placebo score @ 16wk4 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-21.47 vs -13.51 placebo score @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27.83 vs -13.35 placebo score @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.54 vs -21.98 placebo score @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-26.18 vs -14.37 placebo score @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-29.88 vs -21.4 placebo score @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
-23.87 vs -11.89 placebo score @ 16wk2 mg
NCT02576938 · Phase 2 · registry result, not featured evidence
-18.85 vs -13.51 placebo score @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-20.23 vs -13.35 placebo score @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-28.06 vs -21.98 placebo score @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
-18.31 vs -14.37 placebo score @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
-24.82 vs -20.93 placebo score @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-26.08 vs -20.93 placebo score @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
-28.55 vs -20.93 placebo score @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
SCORAD90 2.4% (n=125) vs 0.8% (n=249) placebo @ 16wk4 mg
responder rate · % of participants
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
4.9% (n=123) vs 1.2% (n=244) placebo @ 16wk4 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=92) vs 0% (n=93) placebo @ 16wk4 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
7.2% (n=111) vs 0.9% (n=109) placebo @ 16wk4 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
2.4% (n=123) vs 0.8% (n=249) placebo @ 16wk2 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.1% (n=123) vs 1.2% (n=244) placebo @ 16wk2 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.1% (n=185) vs 0% (n=93) placebo @ 16wk2 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
3.4% (n=146) vs 1.4% (n=147) placebo @ 16wk2 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
3.7% (n=109) vs 0.9% (n=109) placebo @ 16wk2 mg
NCT03733301 · Phase 3 · registry result, not featured evidence
0.8% (n=127) vs 0.8% (n=249) placebo @ 16wk1 mg
NCT03334396 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2% (n=125) vs 1.2% (n=244) placebo @ 16wk1 mg
NCT03334422 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2.2% (n=93) vs 0% (n=93) placebo @ 16wk1 mg
NCT03428100 · Phase 3 · registry result, not featured evidence
2% (n=147) vs 1.4% (n=147) placebo @ 16wk1 mg
NCT03435081 · Phase 3 · registry result, not featured evidence
1.7% (n=121) vs 3.3% (n=122) placebo @ 16wkLow Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
5% (n=120) vs 3.3% (n=122) placebo @ 16wkMedium Dose
NCT03952559 · Phase 3 · registry result, not featured evidence
12.5% (n=120) vs 3.3% (n=122) placebo @ 16wkHigh Dose
NCT03952559 · Phase 3 · registry result, not featured evidence

+ 40 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · ZL-82's landscape